Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Cytek Biosciences (CTKB) Stock Price & Analysis
35 Followers
CTKB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.80 - $9.87
Previous Close$6.15
Volume499.25K
Average Volume (3M)668.96K
Market Cap
$807.33M
Enterprise Value$556.05M
Total Cash (Recent Filing)$262.41M
Total Debt (Recent Filing)$11.13M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 07, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding131,272,929
10 Day Avg. Volume722,157
30 Day Avg. Volume668,963
Standard Deviation0.20
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.13
Price to Sales (P/S)3.90
Price to Cash Flow (P/CF)19.80
P/FCF Ratio22.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit5.08
Enterprise Value/Ebitda-47.06
Forecast
1Y Price Target
$8.25Price Target Upside34.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cytek Biosciences News
Bulls Say, Bears Say
Bulls Say
Executive AppointmentBill McCombe has been appointed as the new CFO of Cytek, bringing over 20 years of investment banking experience and expertise in M&A and capital raising.
Financial PerformanceCTKB reported revenues that were above consensus estimates, indicating a strong performance and potential investor confidence.
Market RecoveryImprovement in customer ordering patterns and management's expectation of heavier weighting of revenue in the second half of the year suggest a recovery in key markets.
Bears Say
Financial PerformanceCTKB's gross margin fell short of expectations because of a one-time inventory expense and increased fixed costs relative to revenue.
Future OutlookRevenue projections for the upcoming fiscal year are lower than what analysts anticipated, indicating a conservative stance in light of economic headwinds.
Sales PerformanceThe company is experiencing prolonged sales cycles in the U.S. and APAC regions, which could threaten upcoming revenue growth.
---
Ownership Overview
19.35% Insiders
17.84% Mutual Funds
20.78% Other Institutional Investors
42.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTKB FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was $3.80 and its highest was $9.87 in the past 12 months.
What is Cytek Biosciences’s market cap?
Currently, no data Available
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on May 08, 2024. The company reported -$0.007 earnings per share for the quarter, beating the consensus estimate of -$0.025 by $0.018.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is >-$0.01.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 131,272,930 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of -$0.007 in its last earnings report, beating expectations of -$0.025. Following the earnings report the stock price went down -1.116%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Among the largest hedge funds holding Cytek Biosciences’s share is RA Capital Management. It holds Cytek Biosciences’s shares valued at 46M.
---
Cytek Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.25 (34.15% Upside)
$8.25 (34.15% Upside)
Blogger Sentiment
Neutral
CTKB Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 17.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.03%
12-Months-Change
Fundamentals
Return on Equity
-2.82%
Trailing 12-Months
Asset Growth
-6.20%
Trailing 12-Months
Company Description
Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
---
CTKB Earnings Call
Q1 2024
0:00 / 0:00
---
CTKB Stock 12 Month Forecast
Average Price Target
$8.25
▲(34.15% Upside)
Technical Analysis
Best Analysts Covering CTKB
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-17.60%
reiterated a buy rating 2 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -17.60% per trade.
---